Selecting the optimal cell therapy manufacturing platform
Abstract: Choosing between modular and fully integrated manufacturing platforms is a critical decision for cell therapy developers, impacting scalability, cost efficiency, and commercial viability. Fully integrated systems offer rapid uptime and simplified workflows but limit flexibility and scalability, while modular platforms provide customization and long-term cost efficiency at the expense of higher upfront investment and operational complexity. The article guides developers through key considerations—cell characteristics, scalability, flexibility, automation—and underscores the importance of early planning and expert support to optimize manufacturing strategies for both autologous and allogeneic therapies.